Q3 2026 Abbott Earnings Conference Call - LIFECELL CORP

Financial Performance:

• Third-quarter comparable sales grew 7%, with Adjusted EPS of $1.42 (up 9% YoY).
• Adjusted gross margin expanded 140 bps YoY to 57.2%, driven by favorable mix, Exact Sciences integration, and operational efficiencies.
• Operating margin increased 40 bps to 23.4%, with R&D at 6.9% of sales and SG&A at 26.9%.
• Foreign exchange headwinds were modest (-0.4% impact in Q3) but expected to reach -1.0% in Q4.
• The company maintains an investment-grade credit profile with a net debt-to-EBITDA ratio of approximately 2.0x, supporting continued dividend growth and potential buybacks.

Guidance and Future Outlook:

• Full-year 2026 sales guidance reduced to 6% growth; Q4 adjusted EPS guidance set at $1.62–$1.67.
• Post-separation, Abbott expects accelerated top-line growth (50–100 bps faster) and margin expansion (gross margin +200+ bps, operating margin +100 bps).
• Management anticipates 2027 top-line growth to be similar to 2026 initially, with a more conservative guidance approach to build confidence for upside execution later in the year.
• Long-term EPS growth target remains around 9% annually, with confidence in maintaining historical beat/miss rates.

Business Segments and Product Lines:

• Medical Devices (Medical Tech): Sales up 8%; EP sales accelerated mid-to-high teens (excl. LAA), led by Volt PFA catheter adoption. Rhythm management grew 10% driven by AVERA pacemaker uptake.
• Diagnostics: Sales up 6.5%; Core lab grew 5.5%, while cancer diagnostics surged 14% (Cologuard +11% and precision oncology). Launched first blood-based colorectal cancer screening test.
• Nutrition: Sales up 5%; Pediatric grew 9% (US up 11%), and adult grew 2%. Strong sequential growth driven by WIC contract wins and retail trends. Launched Similac with whole milk.
• Established Pharmaceuticals (EPD): Sales up 8.5%, with double-digit growth in emerging markets (Asia, LatAm, Middle East).
• Pipeline Highlights: FDA approval for LibreDuo (dual glucose/ketone sensor) expected in December; CE mark for AMOLED 360 LAA device; TactiFlex Duo approval expected Q4.

Market and Competitive Landscape:

• Nutrition market shifting from healthcare-led to consumer/wellness-driven, favoring the upcoming independent entity.
• EP market facing short-term headwinds in the LAA segment due to competitor dynamics and delayed US orders; however, Europe growth was 25%, and Japan expected to turn positive in Q4.
• Diabetes (CGM) market faces pricing pressure in international markets and lack of immediate reimbursement expansion for Type 2 non-insulin users.
• Abbott positions itself as the only company with both stool-based and blood-based colorectal screening options.

Risks and Challenges:

• Litigation: Neonatal necrotizing enterocolitis (NEC) litigation remains active; settlement with 2,000 claimants made in August, but liability remains with Abbott during separation.
• Cybersecurity: A July cyber event temporarily disrupted diagnostics sales, reducing growth by approximately 1 percentage point.
• Pricing & Reimbursement: Potential price erosion in international CGM markets and uncertainty regarding future CMS reimbursement rates for Type 2 non-insulin users.
• LAA Market Dynamics: Temporary order slowdown in the US due to competitor activity and anticipation of new entrants.

Management Commentary and Tone:

• CEO Robert Ford emphasized a strategic shift to separate Nutrition into a standalone S&P 500 company to maximize value, citing distinct market dynamics and growth cycles.
• Tone remains confident and innovation-focused, highlighting a "battle-tested" team and a robust pipeline despite short-term headwinds.
• Management prioritized "prudent" top-line guidance for 2027 to ensure future upside potential while maintaining strong EPS growth and cash flow generation.
• The decision to spin rather than sell Nutrition was driven by desire to avoid tax implications and gain control over the strategic timeline.

Analyst Questions and Answers:

• Strategic Rationale: Ford clarified the spin is to capitalize on healthy nutrition trends and allow faster investment in marketing and M&A, which is harder within the diversified Abbott structure.
• Litigation Liability: Confirmed NEC liability remains with Abbott; both entities will be well-capitalized to handle legal defense.
• Revenue Guidance Reduction: Attributed to temporary EP headwinds (LAA market) and international pricing adjustments in Diabetes, not fundamental demand destruction.
• Pipeline Confidence: Highlighted significant R&D investment (crossing $3B), with focus on Cephia mitral valve, leadless pacing (Averra CSP), and biologic biosimilars.
• M&A Strategy: Spin does not impact M&A capacity; focus remains on tuck-in deals and organic innovation due to limited transformative targets currently in the market.

Other Key Points:

• Separation Structure: Tax-free distribution to shareholders; new Nutrition CEO Daniel Salvadori leads the independent entity with 16,000 employees and ~$8.5B annual sales.
• Expected Completion: Separation anticipated to close by end of next year, subject to approvals.
• Dividend: Combined dividends of Abbott and Nutrition companies will equal Abbott's current dividend at the time of separation.
• Capital Allocation: Plan to raise debt for the new Nutrition company, with proceeds partially distributed to Abbott, while maintaining strong investment-grade ratings for both.
• Innovation: Emphasis on R&D never being cut, with focus on organics and selective tuck-ins to sustain long-term growth.